Ariel T. Gonzalez

Ariel T. Gonzalez

Auto-generated profile, based on publicly available information

Ariel T. Gonzalez

Department of Neurosurgery, Duke University School of Medicine , Durham, NC

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Science Advances
Verified
Journal Article
Open access
MMMulki Mehari
Mulki Mehari
GWGayathri Warrier
Gayathri Warrier
ADAbraham Dada
Abraham Dada
AKAymen Kabir
Aymen Kabir
AHAden P. Haskell-Mendoza
Aden P. Haskell-Mendoza
SHShawn Hervey-Jumper
Shawn Hervey-Jumper
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.

10 December 2025 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
AGAriel T Gonzalez
Ariel T Gonzalez
AHAden P Haskell-Mendoza
Aden P Haskell-Mendoza
EREllery H Reason
Ellery H Reason
JJJoshua D Jackson
Joshua D Jackson
CWChunhao Wang
Chunhao Wang
Peter FecciPeter Fecci
Peter Fecci
Background: Stereotactic radiosurgery (SRS) remains the standard of care for brain metastases (BM), offering effective local control with fewer neurocognitive side effects. However, distinguishing radiation necrosis (RN) from local recurrence (LR) is challenging in lesions that enlarge post-SRS. Identifying clinical and treatment-related factors associated with RN vs LR may improve decision-making. Prior smaller studies have suggested time to progression may help differentiate RN from LR; we aimed to reassess this observation and explore other factors in a larger cohort. Methods: We retrospectively analyzed patients treated with SRS for BM between 2011 and 2022 who later underwent biopsy, with or without LITT, for imaging-suspected RN vs LR. Data included demographics, clinicopathologic characteristics, SRS-treatment parameters, and biopsy results. Results: Among the identified 145 patients with 151 progressive lesions, biopsy confirmed RN in 93 (61.6%) and LR in 58 (38.4%). A subset of lesions (n = 108) had complete dosimetric data. Median age at SRS was 62 years, with a median SRS-biopsy interval of 13 months. The median prescribed dose was 20 Gy for single-fraction and 27.5 Gy for hypofractionated regimens. Multivariable models identified age ≥65 and SRS to biopsy interval ≥9 months as predictors of RN in the full cohort. In the subset group with detailed dosimetric data, V12Gy ≥ median (4.64 cm³) additionally predicted RN and improved model fit. Conclusion: We identified older age, a longer SRS to biopsy interval, and higher V12Gy as predictors of RN. Our predictive models incorporate these variables and may support clinical decision-making, improve diagnostic accuracy, and optimize patient outcomes.